Action CRXT CLARUS THERAPEUTICS HOLDINGS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues Clarus Therapeutics Holdings, Inc.

Actions

CRXT

US18271L1070

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
CLARUS THERAPEUTICS HOLDINGS, INC. : Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Other Events (form 8-K)
Clarus Therapeutics Holdings, Inc. Went Out of Business
CLARUS THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
First Amended Combined Liquidation Plan and Disclosure Statement Approved for Clarus Therapeutics Holdings, Inc.
CLARUS THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
First Motion for Exclusivity Period Extension Approved For Clarus Therapeutics Holdings, Inc.
First Motion for Exclusivity Period Extension Filed by Clarus Therapeutics Holdings, Inc.
CLARUS THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
First Amended Combined Liquidation Plan and Disclosure Statement Approved on Interim Basis for Clarus Therapeutics Holdings, Inc.
First Amended Combined Liquidation Plan and Disclosure Statement Filed by Clarus Therapeutics Holdings, Inc.
Combined Liquidation Plan and Disclosure Statement Filed by Clarus Therapeutics Holdings, Inc.
CLARUS THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
CLARUS THERAPEUTICS HOLDINGS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)
Clarus Therapeutics Holdings, Inc. Announces Termination of Robert Dudley as Chief Executive Officer
Clarus Therapeutics Holdings, Inc. Announces Termination of Steven Bourne as Chief Financial Officer, Effective November 14, 2022
Clarus Therapeutics Holdings, Inc. Announces Executive Changes
Motion for Asset Sale Approved for Clarus Therapeutics Holdings, Inc.
CLARUS THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
CLARUS THERAPEUTICS HOLDINGS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful Bidder
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action CRXT
  4. Actualités Clarus Therapeutics Holdings, Inc.
  5. Autres langues